Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance
03. Oktober 2017 12:00 ET
|
Ritter Pharmaceuticals
Los Angeles, California,, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...